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Cardiovascular mechanisms of
death in severe COPD
exacerbation: time to think and
act beyond guidelines
Leonardo M Fabbri,1 Bianca Beghe´,1
Alvar Agusti2
Three important studies on acute exacer-
bations of chronic obstructive pulmonary
disease (ECOPD)have been published in
Thorax. Two of them, by Chang et al1(see
page 764) and Hoiset et al2 (see page
775), show the importance of the cardiac
biomarkers troponin T and NT-BNP (N-
terminal pro-B-type natriuretic peptide)
as strong predictors of the increased risk
of death of patients hospitalised because
of ECOPD.1 2 The third, by Maclay et al3
(see page 769), provides evidence that
patients with stable chronic obstructive
pulmonary disease (COPD) have
increased circulating plateletemonocyte
aggregatesda potential speciﬁc patho-
genic mechanism of atherosclerosis.
These aggregates further increase during
exacerbations, suggesting a plausible
biological mechanism to explain the
increased cardiovascular risk seen in
ECOPD. Taken together, these studies
conﬁrm the view that ECOPD episodes
requiring hospitalisation must be consid-
ered very severe events in the natural
course of the disease because they are
associated with such important
outcomes as increased risk of mortality,
reduced health status, impaired lung
function, muscle weakness, and cardio-
pulmonary complications.4 The studies
also suggest that the increased risk of
death is often due to acute cardiovascular
involvement, and they highlight the
limitations of the current deﬁnition of
ECOPD and the need to move towards
a more comprehensive deﬁnition, diag-
nostic approach and treatment.
RISK OF DEATH AND EXACERBATIONS OF
COPD
Several previous studies have clearly estab-
lished that episodes of ECOPD are a major
driver of mortality in this disease, especially
during and immediately after the acute
event. (The long-term effects are discussed
in next paragraph.) For instance, in a cohort
of 1016 patients hospitalised because of
ECOPD with hypercarbia (PaCO2$50 mm
Hg), Connors et al5 reported that mortality
was 11% in hospital, and 20%, 33%, 43%
and 49%, respectively, at 60 days, 180 days,
1 year, and 2 years after discharge. More
recently, Chang et al6 reported that
mortality during the ﬁrst 30 days after
hospitalisation varied between 2% and 21%
according to the CURB65 score. CURB65 is
a composite index based on confusion,
blood urea, respiratory rate, blood pressure
and age that was developed to predict
mortality risk in community-acquired
pneumonia.6 Together these studies
demonstrate that mortality during and
immediately after hospitalisation for
ECOPD is remarkably high.
Episodes of ECOPD also affect long-
term mortality. This is best illustrated by
the study of Soler-Cataluña et al,7 who
followed a cohort of 304 patients with
COPD for 5 years and found that
mortality increased in direct proportion to
the frequency of ECOPD; that is, patients
with frequent episodes (three or more)
had the greatest mortality risk (HR 4.13;
95% CI 1.80 to 9.41). In agreement with
Connors et al,5 Soler-Cataluña et al also
found that arterial hypercarbia was an
independent marker of poor prognosis
(HR 1.07; 95% CI 1.02 to 1.12).
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CARDIOVASCULAR DISEASE AND
EXACERBATIONS OF COPD
Cardiovascular disease (CVD) is an
important cause of mortality in COPD,8
and, as recently shown by Donaldson
et al,9 the risk of acute vascular events
appears to be particularly high during
episodes of ECOPD. After analysing data
from 25 857 patients with COPD who
were entered in the Health Improvement
Network database over a 2-year period,
Donaldson et al reported that the risk of
myocardial infarction 1e5 days after an
ECOPD episode increased 2.3-fold (95% CI
1.1 to 4.7; p¼0.03), and that the risk of
stroke 1e49 days after ECOPD increased
1.3-fold (95% CI 1.0 to 1.6; p¼0.05).9
Furthermore, a 2009 retrospective post-
mortem study of patients who died
within 24 h of hospitalisation because of
ECOPD showed that cardiac failure and
thromboembolism were the principal
causes of death.10
The mechanisms linking COPD and
CVD are unclear, but the presence of low-
grade chronic systemic inﬂammation is
likely to be an important one.11e13
Systemic inﬂammation increases during
ECOPD,14 15 providing a potential mech-
anism to explain the increased risk of
vascular events associated with ECOPD.9
The three studies published in this issue
provide new information that can
contribute to a better understanding of
the relationship between ECOPD, inﬂam-
mation and cardiovascular events. The
ﬁrst two studies1 2 found that the plasma
levels of the cardiac biomarkers NT-
proBNP and troponin Twere abnormal in
a signiﬁcant number of patients hospital-
ised because of ECOPD, and that both
markers predicted mortality1 2 even after
adjusting for other predictors of mortality
such as PaCO2 or CURB65 score.1 The
third study found that, compared with
healthy controls, patients with COPD had
increased circulating plateletemonocyte
aggregates, which were further increased
during ECOPD.3 Together these ﬁndings
suggest that cardiovascular involvement
in ECOPD may be an important determi-
nant of prognosis and death, opening new
avenues for research of novel diagnostic
and therapeutic strategies.
LIMITATIONS OF THE CURRENT
DEFINITION OF EXACERBATION OF COPD
Maclay et al3 studied only patients with
ECOPD, excluding those with acute heart
failure, pneumonia or pulmonary embo-
lism. However, Chang et al1 and Hoiset
et al2 do not provide detailed criteria of
inclusion and exclusion, nor the full range
of examinations performed to exclude
alternative or concomitant causes of an
increase in respiratory symptoms that
may mimic an episode of ECOPD.
Unfortunately, the current deﬁnition of
ECOPD is still very much descriptive and
clinical. Episodes of ECOPD are deﬁned as
acute events characterised by a change in
the patient’s baseline dyspnoea, cough,
and/or sputum that is beyond normal day-
to-day variations; in a patient with
underlying COPD, these events may
warrant a change in medication.16e18
However, while this deﬁnition may be
useful in epidemiologic studies,19 it is
often of limited use in the clinical setting.
It is suggested that more than half of
ECOPD episodes are caused by viral and
bacterial infections or pollutants.16e18
These exacerbations are most likely asso-
ciated with the three cardinal respiratory
symptoms, increased sputum, purulent
sputum and dyspnoea. In these cases,
dyspnoea most likely worsens because of
increased inﬂammation of the airways and
the lung due to the infection or pollutant.
However, patients with COPD often have
several concomitant disorders. Therefore
acute inﬂammation of the airways and the
lung may not only worsen dyspnoea by
affecting the respiratory system, but may
also have systemic effects because of acute
systemic inﬂammation and thus cause
dyspnoea by affecting the cardiovascular
or metabolic system. Moreover, other
conditions, such as pulmonary embolism,
acute cardiac failure, pneumonia, pneu-
mothorax and anaemia, can mimic ECOPD
by precipitating respiratory symptoms,
particularly dyspnoea. Considering this
complexity of causes, we suggest that the
term ‘exacerbations of COPD’ be changed
to ‘exacerbations of respiratory symptoms
in patients with COPD’. For the same
reason, there is great interest in identifying
biomarkers that can facilitate a more
precise diagnosis of ECOPD and its aeti-
ology. The three studies published in this
issue suggest that serum biomarkers such
as troponin T and NT-BNP may not only
identify patients at increased risk of death
but may also help to determine the relative
role of extra-respiratory events, such as
acute heart failure or thromboembolism,
and that of other causes of acute dyspnoea
in patients with COPD.
NEED FOR A MORE COMPREHENSIVE
DIAGNOSTIC AND THERAPEUTIC
APPROACH
These three articles1e3 extensively discuss
the mechanisms underlying the increased
levels of cardiac biomarkers and platelet
activation during ECOPD, as well as
their clinical signiﬁcance. The increase in
troponin T and NT-BNP may be due to
several different causes, including systemic
inﬂammation, respiratory failure, coronary
artery disease, left ventricular dysfunction,
right ventricular pressure overload due
to pulmonary hypertension, or pulmonary
thromboembolism. However, platelet
activation might not only be due to
systemic inﬂammation but also to other
concomitant chronic conditions such as
rheumatoid arthritis or diabetes, or acute
conditions such as hypoxaemia, tachy-
cardia and hyperglycemia, all predictors
of poor outcome in patients with
ECOPD.4 8
Guidelines provide clear evidence-based
recommendations on how to diagnose and
treat respiratory abnormalities during
ECOPD episodes, but provide little direc-
tion on how to deal with concomitant
abnormalities in patients with COPD.
Considering the high risk of cardiovascular
complications and death from ECOPD, we
agree with the authors of the three studies
discussed here that, while awaiting the
generation of the necessary scientiﬁc
evidence, patients hospitalised because of
ECOPD should be carefully examined for
the relevant biomarkers and for any
concomitant abnormality that may call
for speciﬁc therapy. This in line with the
recent editorial of FitzGerald20 and
comment by the Editors of Thorax21 who
recommend replacing the term ‘exacerba-
tions’ with the term ‘lung attacks’ to
emphasise their severity, dramatic conse-
quences, and need for more aggressive,
comprehensive and prolonged treatment.
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